知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

315 records (took 0.091 seconds)

    Death domain containing receptor 4 antibodies and methods
    1.
    发明授权
    Death domain containing receptor 4 antibodies and methods 有权
    含有受体4抗体的死亡域和方法

    公开(公告)号：US08329179B2

    公开(公告)日：2012-12-11

    申请号：US12010108

    申请日：2008-01-18

    Applicant: Jian Ni ,  Craig A. Rosen ,  James G. Pan ,  Reiner L. Gentz ,  Vishva M. Dixit

    Inventor： Jian Ni ,  Craig A. Rosen ,  James G. Pan ,  Reiner L. Gentz ,  Vishva M. Dixit

    IPC: A61K39/395 ,  A61K31/00 ,  C07K16/30

    CPC classification number: C07K14/70578 ,  A01K2267/035 ,  C07K16/2878 ,  C07K2319/30

    Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.

    Abstract translation: 本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的新的含有死亡域的受体-4（DR4）蛋白。 特别地，提供编码人DR4蛋白的分离的核酸分子。 还提供了DR4多肽，载体，宿主细胞和用于制备它们的重组方法。 本发明还涉及用于鉴定DR4活性的激动剂和拮抗剂的筛选方法以及使用DR4多核苷酸和多肽的方法。 本发明还涉及使用DR4特异性抗体（其可以是DR4活性的激动剂和/或拮抗剂）的减少或增加的细胞凋亡相关疾病的治疗。

    Neutrokine-alpha fusion proteins
    2.
    发明授权
    Neutrokine-alpha fusion proteins 有权
    Neutrokine-α融合蛋白

    公开(公告)号：US08212004B2

    公开(公告)日：2012-07-03

    申请号：US11054539

    申请日：2005-02-10

    Applicant: Guo-Liang Yu ,  Reinhard Ebner ,  Jian Ni

    Inventor： Guo-Liang Yu ,  Reinhard Ebner ,  Jian Ni

    IPC: C07K14/475 ,  A61K38/16

    CPC classification number: G01N33/56972 ,  A61K31/519 ,  A61K38/00 ,  A61K47/6849 ,  A61K49/0004 ,  A61K2039/505 ,  C07H21/04 ,  C07K14/52 ,  C07K14/70575 ,  C07K14/715 ,  C07K16/24 ,  C07K16/2875 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/622 ,  C07K2317/76 ,  G01N33/564 ,  G01N2333/52 ,  G01N2800/24

    Abstract: The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.

    Abstract translation: 本发明涉及编码Neutrokine-α和/或Neutrokine-αSV多肽的核酸分子，包括细胞外结构域的可溶形式。 还提供了中和型α和/或中枢神经素αSV多肽，载体，宿主细胞和用于制备它们的重组方法。 本发明进一步涉及使用这些抗体特异性结合中枢神经素-α和/或中枢神经素-αSV的抗体或其部分以及诊断和治疗方法。 还提供了用于检测免疫系统相关疾病的诊断方法和使用本发明的组合物治疗免疫系统相关疾病的治疗方法。

    Human tumor necrosis factor receptor-like genes
    4.
    发明授权
    Human tumor necrosis factor receptor-like genes 失效
    人类肿瘤坏死因子受体样基因

    公开(公告)号：US08110659B1

    公开(公告)日：2012-02-07

    申请号：US08718737

    申请日：1996-09-18

    Applicant: John M. Greene ,  Robert D. Fleischmann ,  Jian Ni

    Inventor： John M. Greene ,  Robert D. Fleischmann ,  Jian Ni

    IPC: C07K14/00

    CPC classification number: C07K14/7151 ,  A61K38/00 ,  C12N9/1205 ,  C12N2799/026 ,  Y02A50/58

    Abstract: The present inventors have discovered novel receptors in the Tumor Necrosis Factor (TNF) receptor family. In particular, receptors having homology to the type 2 TNF receptor (TNF-RII) are provided. Isolated nucleic acid molecules are also provided encoding the novel receptors of the present invention. Receptor polypeptides are further provided as are vectors, host cells and recombinant methods for producing the same.

    Abstract translation: 本发明人已经在肿瘤坏死因子（TNF）受体家族中发现了新的受体。 特别地，提供了与2型TNF受体（TNF-RII）具有同源性的受体。 也提供编码本发明的新受体的分离的核酸分子。 进一步提供受体多肽，载体，宿主细胞和用于制备它们的重组方法。

    Tumor necrosis factor-gamma
    5.
    发明授权
    Tumor necrosis factor-gamma 失效
    肿瘤坏死因子-γ

    公开(公告)号：US08093363B2

    公开(公告)日：2012-01-10

    申请号：US12879210

    申请日：2010-09-10

    Applicant: Guo-Liang Yu ,  Jian Ni ,  Craig A. Rosen ,  Jun Zhang

    Inventor： Guo-Liang Yu ,  Jian Ni ,  Craig A. Rosen ,  Jun Zhang

    IPC: C07K16/28 ,  C07K16/18 ,  C07K16/22 ,  C07K16/46 ,  C07K14/525 ,  C12N5/00 ,  G01N33/53

    CPC classification number: A61K51/08 ,  C07K16/241 ,  Y10S930/144

    Abstract: Human TNF-gamma-alpha and TNF-gamma-beta polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides to inhibit cellular growth, for example in a tumor or cancer, for facilitating wound-healing, to provide resistance against infection, induce inflammatory activities, and stimulating the growth of certain cell types to treat diseases, for example restenosis. Also disclosed are diagnostic methods for detecting a mutation in the TNF-gamma-alpha and TNF-gamma-beta nucleic acid sequences or overexpression of the TNF-gamma-alpha and/or TNF-gamma-beta polypeptides. Antagonists against such polypeptides and their use as a therapeutic to treat cachexia, septic shock, cerebral malaria, inflammation, arthritis and graft-rejection are also disclosed.

    Abstract translation: 公开了人类TNF-γ-α和TNF-γ-β多肽和编码这种多肽的DNA（RNA）以及通过重组技术产生此类多肽的方法。 还公开了利用这些多肽抑制细胞生长的方法，例如在肿瘤或癌症中，用于促进伤口愈合，提供抗感染，诱导炎症活性和刺激某些细胞类型的生长以治疗疾病， 示例再狭窄。 还公开了用于检测TNF-γ-α和TNF-γ-β核酸序列中的突变或TNF-γ-α和/或TNF-γ-β多肽的过表达的诊断方法。 还公开了抗这些多肽的拮抗剂及其作为治疗性恶病质，败血性休克，脑疟疾，炎症，关节炎和移植排斥的治疗剂的用途。

    Methods of determining the level of human tumor necrosis factor receptor-like 2
    6.
    发明授权
    Methods of determining the level of human tumor necrosis factor receptor-like 2 失效
    确定人肿瘤坏死因子受体样水平的方法2

    公开(公告)号：US07910321B2

    公开(公告)日：2011-03-22

    申请号：US12235837

    申请日：2008-09-23

    Applicant: Jian Ni ,  Craig A. Rosen ,  Reiner L. Gentz ,  Sally Doreen P. Lyn ,  Mark Hurle

    Inventor： Jian Ni ,  Craig A. Rosen ,  Reiner L. Gentz ,  Sally Doreen P. Lyn ,  Mark Hurle

    IPC: G01N33/48 ,  G01N33/53 ,  G01N33/563 ,  G01N33/577

    CPC classification number: C07K14/7151

    Abstract: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.

    Abstract translation: 本发明涉及肿瘤坏死因子家族受体的新成员。 本发明提供编码人TR2受体的分离的核酸分子及其两个剪接变体。 还提供TR2多肽，载体，宿主细胞和用于制备它们的重组方法。 本发明还涉及用于鉴定TR2受体活性的激动剂和拮抗剂的筛选方法。 还提供了用于检测与TR2受体的异常表达相关的疾病状态的诊断方法。 还提供了治疗与表达TR2受体的细胞的异常增殖和分化相关的疾病状态的治疗方法。

    DR3 antibodies
    8.
    发明授权
    DR3 antibodies 失效
    DR3抗体

    公开(公告)号：US07708996B2

    公开(公告)日：2010-05-04

    申请号：US12046107

    申请日：2008-03-11

    Applicant: Guo-Liang Yu ,  Jian Ni ,  Reiner L. Gentz ,  Patrick J. Dillon

    Inventor： Guo-Liang Yu ,  Jian Ni ,  Reiner L. Gentz ,  Patrick J. Dillon

    IPC: A61K39/395 ,  C07K16/18 ,  C07K16/28

    CPC classification number: C07K14/4747 ,  A61K38/00 ,  A61K48/00 ,  C07K14/705 ,  C07K14/70578 ,  C07K16/2878 ,  C07K2317/21 ,  C12N2799/026

    Abstract: The present invention relates to novel Death Domain Containing Receptor (DR3 and DR3-V1) proteins that are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR3 and DR3-V1 proteins. DR3 and DR3-V1 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are antibodies and fragments thereof that bind to polypeptides of the invention. The invention further relates to screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity.

    Abstract translation: 本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的新型死亡域含有受体（DR3和DR3-V1）蛋白。 特别地，提供编码人DR3和DR3-V1蛋白的分离的核酸分子。 还提供DR3和DR3-V1多肽，载体，宿主细胞以及用于制备它们的重组方法也是如此。 还提供了结合本发明多肽的抗体及其片段。 本发明还涉及用于鉴定DR3和DR3-V1活性的激动剂和拮抗剂的筛选方法。

    Death domain containing receptor 4 antibody and methods
    10.
    发明授权
    Death domain containing receptor 4 antibody and methods 有权
    含有受体4抗体的死亡域和方法

    公开(公告)号：US07476384B2

    公开(公告)日：2009-01-13

    申请号：US11076187

    申请日：2005-03-10

    Applicant: Jian Ni ,  Craig A. Rosen ,  James Pan ,  Reiner L. Gentz ,  Vishva M. Dixit

    Inventor： Jian Ni ,  Craig A. Rosen ,  James Pan ,  Reiner L. Gentz ,  Vishva M. Dixit

    IPC: A61K39/395 ,  A61K38/21 ,  C07K14/56 ,  C07K14/705

    CPC classification number: C07K14/70578

    Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.

    Abstract translation: 本发明涉及作为肿瘤坏死因子（TNF）受体家族成员的新的含有死亡域的受体-4（DR4）蛋白。 特别地，提供编码人DR4蛋白的分离的核酸分子。 还提供了DR4多肽，载体，宿主细胞和用于制备它们的重组方法。 本发明还涉及用于鉴定DR4活性的激动剂和拮抗剂的筛选方法以及使用DR4多核苷酸和多肽的方法。 本发明还涉及使用DR4特异性抗体（其可以是DR4活性的激动剂和/或拮抗剂）的减少或增加的细胞凋亡相关疾病的治疗。

Patent Agency Ranking